跳至主要内容
临床试验/CTRI/2024/10/075322
CTRI/2024/10/075322尚未招募2/3 期

A comparative clinical to evaluate the efficacy of prabhakara vati with sarpagandha vati in shonita dusti with special reference to essential hypertension

Jyoti Ashok Belavi1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2024年10月20日最近更新:

试验速览

阶段
2/3 期
状态
尚未招募
发起方
入组人数
40
试验地点
1
主要终点
Headache reduced

研究概览

简要总结

The samanya chikitsa of Shonita dusti is Raktapittahara kriya, Virechana, Upavasaa and Rakta sravana . In that Raktapittahara kriya plays vital role in planning the treatment,which mainly aimed as Vyadhipratyanika and Samprapti vighatana Chikitsa.

On classical literature analysis the main siddhanta of chikitsa is Samprapti vighatana of the disease. Prabhakar vati is one such drug which is mentioned in Hrudrogadhikar of Bhaishajya Ratnavali. Its constituents helps to do Samprapti vighatana of Shonita dusti and also helps to prevent further complications caused by Essential hypertension, as it contains swarnamakshika bhasma, Loha bhasma, Abhraka bhasma, Vamshalochana, Shilajatu and Arjuna kwath as bhavana dravya

. It is having Madhura, Tikta rasa, Sheeta veerya and overall karmukata is Pitta Shamana with Tridosha hara properties. Thus does the Shamana of Vyadhis caused by Shonita dusti . Hence Prabhakra vati is choosen for the current study.Sarpagandha vati is explained under Brama-Anidra-Unmad adhikar of Siddhayoga sangraha and it contains Sarpagandha, Jatamansi, Parasika Yavani, Pippalimoola, Bhanga.Sarpagandha vati is having predominantly having Tikta rasa and act as Raktashodhaka. It is nidrajanak and a nutrient for brain, which can be used to relieve anxiety, stress and mental fatigue

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
30.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Patients presenting with samanya lakshana of Shonita dusti.

排除标准

  • Patients with history of cerebrovascular accident, chronic kidney disease.
  • diabetic mellitus other systemic,Metabolic disorders.
  • Patients having secondary hypertension.
  • Patients with history of Disorders related with haemopoietic system like Leukemia Hemophilia Unconscious, Coma patient, and Patients who are suffering with Gastro-intestinal bleeding disorders.

结局指标

主要结局

Headache reduced

时间窗: After 14 days

次要结局

  • Improved in generalised weakness and daily activities(After 21 days of treatment)

研究者

发起方
Jyoti Ashok Belavi
申办方类型
Private medical college
责任方
Principal Investigator
主要研究者

Jyoti Ashok Belavi

Shri Shivayoogeeshwar Rural Ayurvedic College Hospital Inchal

研究点 (1)

Loading locations...

相似试验